Journal of Zhejiang University SCIENCE B

, Volume 13, Issue 3, pp 203–208 | Cite as

Evaluation of intratympanic dexamethasone for treatment of refractory sudden sensorineural hearing loss

  • Yao-wen Wang
  • Ji-hao Ren
  • Yong-de Lu
  • Tuan-fang Yin
  • Ding-hua Xie
Article

Abstract

Objective

To observe and compare the efficacy of intratympanic application of dexamethasone (DXM) for the treatment of refractory sudden sensorineural hearing loss (SSNHL), the DXM was given in three different ways: by tympanic membrane injection, by drip through a ventilation tube, and by perfusion through a round window catheter.

Methods

We conducted a nonrandomized retrospective clinical trial involving 55 patients with refractory SSNHL. For 21 patients (the perfusion group), DXM (2.5 mg/0.5 ml) was perfused transtympanically through a round window catheter using an infusion pump for 1 h twice a day for 7 d giving a total amount of 35.0 mg. For 23 patients (the injection group), DXM (2.5 mg/time) was injected by tympanic membrane puncture at intervals of 2 d on a total of four occasions giving a total amount of 10.0 mg. For 11 patients (the drip group), DXM (2.5 mg/0.5 ml) was dripped via a ventilation tube placed by myringotomy, once on the first day and twice a day for the remaining 6 d giving a total amount of 32.5 mg. Thirty-two patients with refractory SSNHL who refused to undertake further treatments were defined as the control group. Hearing recovery and complications were compared among the groups. Hearing results were evaluated based on a four-frequency (0.5, 1.0, 2.0, 4.0 kHz) pure tone average (PTA).

Results

Post-treatment audiograms were obtained one month after treatments were completed. The improvements in average PTA for the perfusion, injection, and drip groups were 9.0, 8.6, and 1.7 dB, respectively. Hearing improvement was significantly greater in the perfusion and injection groups than in the control group (1.4 dB) (P<0.05). In the perfusion group, 8 out of 21 patients (38.1%) had a PTA improvement of 15–56 dB (mean 29.8 dB); in the injection group, 8 out of 23 patients (34.8%) had a PTA improvement of 16–54 dB (mean 24.9 dB); in the drip group, 1 of 11 patients (9.1%) had a PTA improvement of 26.0 dB; in the control group, 3 out of 32 patients (9.4%) had a PTA improvement of 15–36 dB (mean 14.9 dB).

Conclusions

Topical intratympanic application of DXM is a safe and effective method for the treatment of SSNHL cases that are refractory to conventional therapies.

Key words

Sudden sensorineural hearing loss Dexamethasone Intratympanic Round window 

CLC number

R764.43+7 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Banerjee, A., Parnes, L.S., 2005. Intratympanic corticosteroids for sudden idiopathic sensorineural hearing loss. Otol. Neurotol., 26(5):878–881. [doi:10.1097/01.mao.0000185052.07513.5a]PubMedCrossRefGoogle Scholar
  2. Barrs, D.M., 2004. Intratympanic corticosteroids for Meniere’s disease and vertigo. Otolaryngol. Clin. North Am., 37(5): 955–972. [doi:10.1016/j.otc.2004.03.004]PubMedCrossRefGoogle Scholar
  3. Chen, C.Y., Halpin, C., Rauch, S.D., 2003. Oral steroid treatment of sudden sensorineural hearing loss: a ten year retrospective analysis. Otol. Neurotol., 24(5):728–733. [doi:10.1097/00129492-200309000-00006]PubMedCrossRefGoogle Scholar
  4. Choung, Y.H., Park, K., Shin, Y.R., Cho, M.J., 2006. Intratympanic dexamethasone injection for refractory sudden sensorineural hearing loss. Laryngoscope, 116(5):747–752. [doi:10.1097/01.mlg.0000205183.29986.f6]PubMedCrossRefGoogle Scholar
  5. Dodson, K.M., Sismanis, A., 2004. Intratympanic perfusion for the treatment of tinnitus. Otolaryngol. Clin. North Am., 37(5):991–1000. [doi:10.1016/j.otc.2004.03.003]PubMedCrossRefGoogle Scholar
  6. Fetterman, B.L., Saunders, J.E., Luxford, W.M., 1996. Prognosis and treatment of sudden sensorineural hearing loss. Am. J. Otol., 17(4):529–536.PubMedGoogle Scholar
  7. Gianoli, G.J., Li, J.C., 2001. Transtympanic steroids for treatment of sudden hearing loss. Otolaryngol. Head Neck Surg., 125(3):142–146. [doi:10.1067/mhn.2001.117162]PubMedCrossRefGoogle Scholar
  8. Haynes, D.S., O’Malley, M., Cohen, S., Watford, K., Labadie, R.F., 2007. Intratympanic dexamethasone for sudden sensorineural hearing loss after failure of systemic therapy. Laryngoscope, 117(1):3–15. [doi:10.1097/01.mlg.0000245058.11866.15]PubMedCrossRefGoogle Scholar
  9. Herr, B.D., Marzo, S.J., 2005. Intratympanic steroid perfusion for refractory sudden sensorineural hearing loss. Otolaryngol. Head Neck Surg., 132(4):527–531. [doi:10.1016/j.otohns.2004.09.138]PubMedCrossRefGoogle Scholar
  10. Hughes, G.S., Freedman, M.A., Haberkamp, T.J., Guay, M.E., 1996. Sudden sensorineural hearing loss. Otolaryngol. Clin. North Am., 29(3):393–405.PubMedGoogle Scholar
  11. Jeyakumar, A., Frencis, D., Doerr, T., 2006. Treatment of idiopathic sudden sensorineural hearing loss. Acta Otolaryngol., 126(7):708–713. [doi:10.1080/00016480500504234]PubMedCrossRefGoogle Scholar
  12. Kopke, R., Hoffer, M., Wester, D., 2001. Targeted topical steroid therapy in sudden sensorineural hearing loss. Otol. Neurotol., 22(4):475–479. [doi:10.1097/00129492-2001 07000-00011]PubMedCrossRefGoogle Scholar
  13. Lefebvre, P.P., Staecker, H., 2002. Steroid perfusion of the inner ear for sudden sensorineural hearing loss after failure of conventional therapy: a pilot study. Acta Otolaryngol., 122(7):698–702. [doi:10.1080/003655402/000028037]PubMedCrossRefGoogle Scholar
  14. Lu, Y.D., Ren, J.H., Wu, W.J., Yin, T.F., Tang, Y.Y., Xie, D.H., 2006. Intratympanic dexamethasone for sudden sensorineural hearing loss. J. Clin. Otorhinolaryngol., 20:11–12 (in Chinese).Google Scholar
  15. Parnes, L.S., Sun, A.H., Freeman, J., 1999. Corticosteroid pharmacokinetics in the inner ear fluids: an animal study followed by clinical application. Laryngoscope, 109(s91): 1–17. [doi:10.1097/00005537-199907001-00001]PubMedCrossRefGoogle Scholar
  16. Rauch, S.D., 2004. Intratympanic steroids for sensorineural hearing loss. Otolaryngol. Clin. North Am., 37(5): 1061–1074. [doi:10.1016/j.otc.2004.04.004]PubMedCrossRefGoogle Scholar
  17. Ren, J.H., Lu, Y.D., Yin, T.F., Liu, B., Ge, Y.L., 2006. Intratympanic dexamethasone injection for intractable sudden sensorineural hearing loss. J. Clin. Otorhinolaryngol., 20:219–221 (in Chinese).Google Scholar
  18. Roebuck, J., Chang, C.Y., 2006. Efficacy of steroid injection on idiopathic sudden sensorineural hearing loss. Otolaryngol. Head Neck Surg., 135(2):276–279. [doi:10.1016/j.otohns.2006.03.035]PubMedCrossRefGoogle Scholar
  19. Wilson, W.R., Byl, F.M., Laird, N., 1980. The efficacy of steroids in the treatment of idiopathic sudden hearing loss: a double-blind clinical study. Arch. Otolaryngol., 106(12): 772–776. [doi:10.1001/archotol.1980.00790360050013]PubMedCrossRefGoogle Scholar
  20. Zadeh, M.H., Storper, I.S., Spitzer, J.B., 2003. Diagnosis and treatment of sudden-onset sensorineural hearing loss: a study of 51 patients. Otolaryngol. Head Neck Surg., 128(1):92–98. [doi:10.1067/mhn.2003.50]PubMedCrossRefGoogle Scholar

Copyright information

© Zhejiang University and Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Yao-wen Wang
    • 1
  • Ji-hao Ren
    • 2
  • Yong-de Lu
    • 2
  • Tuan-fang Yin
    • 2
  • Ding-hua Xie
    • 2
  1. 1.Otolaryngology-Head and Neck Surgery DepartmentNingbo First HospitalNingboChina
  2. 2.Otolaryngology-Head and Neck Surgery Department, the Second Xiangya HospitalCentral South UniversityChangshaChina

Personalised recommendations